Recursion Pharmaceuticals (RXRX) PT Raised to $5.50 at Morgan Stanley
Tweet
Share
E-mailGet Alerts RXRX Hot Sheet
Price: $3.18 -1.55%
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Join SI Premium – FREE
Morgan Stanley analyst Sean Laaman raised the price target on Recursion Pharmaceuticals (NASDAQ: RXRX) to $5.50 (from $5.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Incyte (INCY) PT Raised to $105 at Truist Securities
- Credo Tech (CRDO) PT Raised to $350 at Stifel
- Primaris REIT (PMZ-U:CN) PT Raised to Cdn$25 at CIBC
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
